| HOME >> BIOLOGY >> TECHNOLOGY |
capitalized costs.
ANGIOTECH PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(in thousands of
U.S.$, except
share and per Year ended Year ended
share data) December 31, 2007 December 31, 2006
-------------------------------------------------------------------------
Adjust- Adjust-
Reported ments Adjusted Reported ments Adjusted
REVENUE
Royalty revenue 116,659 116,659 175,254 (9,000)a 166,254
Product sales, net 170,193 2,579 b 172,772 138,590 138,590
License fees 842 (842)c - 1,231 (1,231)c -
-------------------------------------------------------------------------
287,694 1,737 289,431 315,075 (10,231) 304,844
-------------------------------------------------------------------------
EXPENSES
License and royalty
fees 18,652 18,652 25,409 25,409
Cost of products
sold 95,529 (2,645)d 92,884 68,263 68,263
Research and
development 53,963 (4,582)e 49,381 45,393 (2,490)e 42,903
Selling, general
and administrative 99,713 (16,868)f 82,845 78,732 (17,262)f 61,470
Depreciation and
amortization 33,429 (29,971)g 3,458 36,014 (32,707)g 3,307
In-process research
and development 8,125 (8,125)h - 1,042 (1,042)h -
-------------------------------------------------------------------------
309,411 (62,191) 247,220 254,853 (53,501) 201,352
-----------------------------------------------------------
'/>"/>
| SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |